The isolation and culture of a pure population of quiescent satellite cells, a muscle stem cell population, is essential to the understanding of muscle stem cell biology and regeneration, as well as stem cell transplantation for therapies in muscular dystrophy and other degenerative diseases.
Muscle satellite cells are a stem cell population required for postnatal skeletal muscle development and regeneration, accounting for 2-5% of sublaminal nuclei in muscle fibers. In adult muscle, satellite cells are normally mitotically quiescent. Following injury, however, satellite cells initiate cellular proliferation to produce myoblasts, their progenies, to mediate the regeneration of muscle. Transplantation of satellite cell-derived myoblasts has been widely studied as a possible therapy for several regenerative diseases including muscular dystrophy, heart failure, and urological dysfunction. Myoblast transplantation into dystrophic skeletal muscle, infarcted heart, and dysfunctioning urinary ducts has shown that engrafted myoblasts can differentiate into muscle fibers in the host tissues and display partial functional improvement in these diseases. Therefore, the development of efficient purification methods of quiescent satellite cells from skeletal muscle, as well as the establishment of satellite cell-derived myoblast cultures and transplantation methods for myoblasts, are essential for understanding the molecular mechanisms behind satellite cell self-renewal, activation, and differentiation. Additionally, the development of cell-based therapies for muscular dystrophy and other regenerative diseases are also dependent upon these factors.
However, current prospective purification methods of quiescent satellite cells require the use of expensive fluorescence-activated cell sorting (FACS) machines. Here, we present a new method for the rapid, economical, and reliable purification of quiescent satellite cells from adult mouse skeletal muscle by enzymatic dissociation followed by magnetic-activated cell sorting (MACS). Following isolation of pure quiescent satellite cells, these cells can be cultured to obtain large numbers of myoblasts after several passages. These freshly isolated quiescent satellite cells or ex vivo expanded myoblasts can be transplanted into cardiotoxin (CTX)-induced regenerating mouse skeletal muscle to examine the contribution of donor-derived cells to regenerating muscle fibers, as well as to satellite cell compartments for the examination of self-renewal activities.
Muscle satellite cells are a small population of myogenic stem cells located beneath the basal lamina of skeletal muscle fibers. They are characterized by the expression of Pax7, Pax3, c-Met, M-cadherin, CD34, Syndecan-3, and calcitonin1-3. Satellite cells have proven to be responsible for muscle regeneration as muscle stem cells. In adult muscle, satellite cells are normally mitotically quiescent4-8. Following injury, satellite cells are activated, initiate expression of MyoD, and enter the cell cycle to expand their progeny, termed myogenic precursor cells or myoblasts3. After several rounds of cell division, myoblasts exit the cell cycle and fuse to each other in order to undergo differentiation into multi-nucleated myotubes, followed by mature muscle fibers. Myoblasts isolated from adult muscle can readily be expanded ex vivo. The capacity for myoblasts to become muscle fibers in regenerating muscle and to form ectopic muscle fibers in nonmuscle tissues is exploited by myoblast transplantation, a potential therapeutic approach for Duchenne muscular dystrophy (DMD)4, urological dysfunction9, and heart failure10. Indeed, myoblasts have been successfully transplanted in the muscle of both mdx (DMD model) mice and DMD patients11-14. The injected normal myoblasts fuse with host muscle fibers to improve the histology and function of the diseased muscle. Previous work demonstrated that subpopulations of myoblasts are more stem cell-like and remain in an undifferentiated state longer in muscle during muscle regeneration5. Recent work has shown that freshly isolated satellite cells from adult muscle contain a stem cell-like population that exhibits more efficient engraftment and self-renewal activity in regenerating muscle5-8. Therefore, purification of a pure population of quiescent satellite cells from adult skeletal muscle is essential for understanding the biology of satellite cells, myoblasts and muscle regeneration, and for the development of cell-based therapies.
However, current prospective purification methods of quiescent satellite cells require the use of an expensive fluorescence-activated cell sorting (FACS) machine1,2,6-8. In addition, FACS laser exposure tends to induce cell death during separation, which causes lower yield of quiescent satellite cells15. Here, we present a new method for the rapid, economical, and reliable purification of quiescent satellite cells from adult mouse skeletal muscle. This method utilizes enzymatic dissociation followed by magnetic-activated cell sorting (MACS). Following isolation of pure quiescent satellite cells, these cells can be cultured to obtain large numbers of myoblasts after several passages. We also show that intramuscular injection of these freshly isolated quiescent satellite cells or ex vivo expanded myoblasts can be transplanted into cardiotoxin (CTX)-induced regenerating mouse skeletal muscle to examine the contribution of donor-derived cells to regenerating muscle fibers, as well as to satellite cell compartments for the examination of self-renewal activities.
In this protocol, quiescent satellite cells can be easily purified from adult skeletal muscle of mice by collagenase digestion and surface antibody-mediated MACS separation. This method takes approximately 6 hours and does not need any expensive equipment such as a FACS machine. In addition, this method is relatively inexpensive compared to surface antibody-mediated FACS separation. A higher yield of quiescent satellite cells is also expected in comparison to FACS for this method since FACS laser exposure tends to induce…
The authors have nothing to disclose.
We thank Dr. Shahragim Tajbakhsh for providing Myf5+/nLacZ mice. We also thank Alexander Hron and Michael Baumrucker for critical reading of this manuscript. This work was supported by grants from the Muscular Dystrophy Association (MDA) and Gregory Marzolf Jr. MD Center Award.
Materials | |||
Collagenase Type 2 | Worthington | CLS-2 | 100 mg |
Marigel | BD Biosciences | 356234 | 5 ml |
DMEM | Gibco-Invitrogen | 10569010 | 500 ml |
Collagen (Rat Tail) | BD Biosciences | 354236 | 100 mg (3-4 mg/ml) |
Acetic Acid | Sigma-Aldrich | 320099-500ML | 500 ml |
bFGF, human, Recombinant | Gibco-Invitrogen | PHG0263 | 1 mg |
Bovine Serum Albumin (BSA) | Sigma-Aldrich | A5611-1G | 1 g |
Ham’s F10 Medium | Gibco-Invitrogen | 11550-043 | 500 ml |
Fetal Bovine Serum (FBS) | Fisher Scientific | 3600511 | 500 ml |
Horse Serum | Gibco-Invitrogen | 26050088 | 500 ml |
Penicillin/Streptmycin | Gibco-Invitrogen | 15640055 | 100 ml |
Phosphate Buffered Saline | Gibco-Invitrogen | 14190144 | 500 ml |
0.25% Trypsin/EDTA | Gibco-Invitrogen | 25200072 | 500 ml |
18G needle with 12cc Syringe | Fisher Scientific | 22-256-563 | |
Cell strainer (70 μm) | Fisher Scientific | 22-363-548 | |
Falcon 50 ml tube | BD Biosciences | 352098 | |
Falcon 15 ml tube | BD Biosciences | 352097 | |
10 cm tissue culture plate | BD Biosciences | 353003 | |
6 cm tissue culture plate | BD Biosciences | 353004 | |
Falcon 10 ml disposable pipet | BD Biosciences | 357551 | |
Anti-CD31 antibody-PE | eBiosciences | 12-0311 | |
Anti-CD45 antibody-PE | eBiosciences | 30-F11 | |
Anti-Sca1 antibody-PE | eBiosciences | Dec-81 | |
Anti-Integrin α7 antibody | MBL International | ABIN487462 | |
Anti-PE MicroBeads | Miltenyi Biotec | 130-048-801 | |
Anti-Mouse IgG MicroBeads | Miltenyi Biotec | 130-048-402 | |
Mini & MidiMACS Starting Kit | Miltenyi Biotec | 130-091-632 | |
MS Column | Miltenyi Biotec | 130-042-201 | |
LD Column | Miltenyi Biotec | 130-042-901 | |
Cardiotoxin | Sigma Aldrich | C9759-1MG | Stock 10 μM in PBS |
31G Insulin syringe | BD Biosciences | 328438 | |
Refrigerated Microcentrifuge (Microfuge 22R) | Beckman Coulter | 368826 | |
S241.5 Swinging Bucket Rotor | Beckman Coulter | 368882 | |
Refrigerated Centrifuge (Allegra X-22R) | Beckman Coulter | 392187 | |
Nod/Scid immunodeficient mice | Charles River Laboratories | Strain Code 394 | Use 2 months old mice |
Reagents | |||
Name of the reagent | Recipie | ||
10% and 2% FBS DMEM | DMEM (Gibco-Invitrogen #10569010) with 10% or 2% FBS (Fisher Scientific #03600511) and 1% Penicillin/Streptomycin (Gibco-Invitrogen #15640055). | ||
0.2% Collagenase solution | Collagenase Type 2 (Worthington, #CLS-2), Stock: 50 ml: 100 mg Collagenase Type 2 in 10% FBS DMEM. | ||
10% Matrigel solution | Matrigel (BD Biosciences: #356234) is placed on ice for thawing overnight. Five ml Matrigel is dilute by 45 ml DMEM and 5 ml aliquots are stored at -20°C until use. | ||
Matrigel-coated plate | Five ml of 10% Matrigel solution is placed on ice for thawing and is used for coating 10 cm plate at room temprature for 1 minutes. The plate is placed in 5% CO2 incubator at 37°C for 30 minute after removing Matrigel solution, and let the plate dry in culture hood for another 30 minutes. Removed 10% Matrigel solution is stored at -20°C for reusing. | ||
0.01% Collagen solution | Mix to final: 0.01% Collagen (Collagen, Rat Tail: BD Biosciences #354236) in 0.2% acetic acid (320099-500ML) in ddH2O. | ||
Collagen-coated plate | Add 5 ml or 2 ml of Collagen solution to a 10 cm or 6 cm tissue culture plate and let sit at room temperature for three hours. Then, aspirate off liquid and allow to dry in culture hood for 30 min to overnight. Plates can be stored at room temperature for several months. | ||
bFGF stock solution | bFGF, Human, Recombinant (Gibco-Invitrogen #PHG0263, 1 mg) is dissolved with 0.1% BSA solution consisting of 1 mg BSA (Sigma-Aldrich #A5611-1G) and 2 ml ddH2O (0.5 mg/ml bFGF). Aliquot 20 μl in 500 μl microcentrifuge tubes and kept in -80°C. | ||
Myoblast medium | 500 mL HAM’S F10 Medium (Gibco-Invitrogen #11550-043) supplemented with 20% FBS (Fisher Scientific #03600511), Penicillin/streptomycin (Gibco-Invitrogen #15640055), and 10 μg of bFGF (20 μl of bFGF stock). | ||
Differentiation medium | 500 mL DMEM (Gibco-Invitrogen #10569010) supplemented with 5% Horse serum (Gibco-Invitrogen #26050088) and 1% Penicillin/streptomycin (Gibco-Invitrogen #15640055). | ||
10 μM Cardiotoxin stock | 1 mg Cardiotoxin (EMD Millipore #217504-1MG) is dissolved with 13.9 ml PBS. |